Clinical trial • Phase IV|Phase II • Dermatology

GLUCOSE for Severe burns

Phase IV|Phase II trial of GLUCOSE for Severe burns. None/Not specified-controlled. 15 participants.

Overview

Trial Therapeutic Area
Dermatology
Trial Disease
Severe burns
Trial Stage
Phase IV|Phase II
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
13-05-2024
First CTIS Authorization Date
03-09-2024

Trial design

None/Not specified-controlled Phase IV|Phase II trial across 1 site in France.

Comparator
None/Not specified
Target Sample Size
15
Trial Duration For Participant
4

Eligibility

Recruits 15 Vulnerable population is selected. Written consent is required from the patient; if the patient is unable to sign/express consent, consent may be obtained from the trusted person, family or relatives. Emergency inclusion is permitted if the patient is unable to express consent and neither the trusted person nor any family/relatives are present. Patients under guardianship, curatorship or safeguard of justice are excluded..

Pregnancy Exclusion
Pregnant, parturient or breast-feeding women
Vulnerable Population
Vulnerable population is selected. Written consent is required from the patient; if the patient is unable to sign/express consent, consent may be obtained from the trusted person, family or relatives. Emergency inclusion is permitted if the patient is unable to express consent and neither the trusted person nor any family/relatives are present. Patients under guardianship, curatorship or safeguard of justice are excluded.

Inclusion criteria

  • {"criterion_text":"- Patients over 18 years of age"}
  • {"criterion_text":"- Patients hospitalized with burns of at least 30% of body surface area o By a thermal mechanism o At the CHR Metz-Thionville burn center o managed within the 8 hours post-burn"}
  • {"criterion_text":"- Patient affiliated to a social security scheme"}
  • {"criterion_text":"- Written consent obtained from the patient (or from the trusted person, family or relatives if the patient is unable to sign/express consent) or emergency inclusion if the patient is unable to express consent and neither the trusted support person nor any member of the family or relatives is present at the time of inclusion"}

Exclusion criteria

  • {"criterion_text":"- Diabetic patients on insulin"}
  • {"criterion_text":"- Cognitive impairment or language barrier"}
  • {"criterion_text":"- Patient with a CONTRAINDICATION to GLUCOSE 30% PROAMP, solution for injection"}
  • {"criterion_text":"- Patients with pre-hospital cardiac arrest"}
  • {"criterion_text":"- Patient with extra corporeal circulation : Extra Corporeal Membranous Oxygenation (ECMO) or Extra Corporeal Life Support (ECLS) or CRRT (Continuous Renal Replacement Therapy)"}
  • {"criterion_text":"- Patient without central venous line or arterial catheter"}
  • {"criterion_text":"- Patient moribund or immediately subject to therapeutic limitation"}
  • {"criterion_text":"- Impossibility of trans-pulmonary thermodilution monitoring (vascular access difficulties)"}
  • {"criterion_text":"- Pregnant, parturient or breast-feeding women"}
  • {"criterion_text":"- Patient under guardianship, curatorship or safeguard of justice"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- The IDVG is calculated according to the method described by Hitota et al. A reference blood glucose level is measured on an arterial blood sample (arterial catheter) by a blood glucose meter. A bolus of 5 g of glucose is injected into a central venous line over 30 seconds. A second blood glucose level is measured 3 minutes after the end of the injection. The difference between the two blood glucose levels is recorded as d[glu] in mg/dl. IDVG = 24.4 x e(-0.0298 * d[glu]) + 2.7 in liters","definition_or_measurement_approach":"IDVG calculated per Hitota et al.: measure arterial reference blood glucose, inject 5 g glucose bolus via central venous line over 30 seconds, measure second arterial glucose 3 minutes after injection, record difference d[glu] (mg/dl); compute IDVG = 24.4 x e(-0.0298 * d[glu]) + 2.7 (liters)."}

Secondary endpoints

  • {"endpoint_text":"- ITBV (intra-thoracic blood volume) and EVLW (extra-vascular lung water) measured at the same time as IDVG, using the PiCCO device and trans-lung dilution of a thermal indicator (cold saline).","definition_or_measurement_approach":"Measured concurrently with IDVG using the PiCCO device via trans-pulmonary thermodilution (thermal indicator: cold saline)."}
  • {"endpoint_text":"- Body surface area assessed on admission (Wallace method)","definition_or_measurement_approach":"Assessment of body surface area on admission using the Wallace method."}
  • {"endpoint_text":"- Water intake and input/output balance (water intake minus diuresis)","definition_or_measurement_approach":"Calculation of water balance as water intake minus diuresis (input/output recording)."}
  • {"endpoint_text":"- In-hospital mortality","definition_or_measurement_approach":"Recording of mortality occurring during hospital stay."}
  • {"endpoint_text":"- Arterial blood glucose levels will be measured in g/L just before and 3 minutes after the end of the glucose bolus injection, using a glucometer.","definition_or_measurement_approach":"Arterial blood glucose measured in g/L with a glucometer immediately before and 3 minutes after glucose bolus injection."}

Recruitment

Planned Sample Size
15
Recruitment Window Months
28
Consent Approach
Written consent obtained from the patient; if the patient is unable to sign/express consent, consent may be obtained from the trusted person, family or relatives. Emergency inclusion allowed if patient unable to express consent and neither the trusted support person nor any family/relatives is present at time of inclusion.

Geography

Total Number Of Sites
1
Total Number Of Participants
15

France

Earliest CTIS Part Ii Submission Date
09-07-2024
Latest Decision Or Authorization Date
03-09-2024
Processing Time Days
56
Number Of Sites
1
Number Of Participants
15

Sites

Site Name
Centre Hospital Region Metz Thionville
Department Name
Centre de Traitement des Grands-Brûlés
Principal Investigator Name
Serge LE TACON
Principal Investigator Email
serge.le-tacon@chr-metz-thionville.fr
Contact Person Name
Serge LE TACON
Number Of Participants
15

Sponsor

Primary sponsor

Full Name
Centre Hospital Region Metz Thionville
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
France

Investigational products

Investigational Product Name
GLUCOSE 30 % PROAMP, solution injectable
Active Substance
GLUCOSE
Modality
Small molecule
Routes Of Administration
IV INJECTION, IV INFUSION
Route
IV (central venous line)
Authorisation Status
Marketing authorisation number: 34009 371 747 7 0 (France)
Starting Dose
5 g bolus
Dose Levels
5 g (single bolus for IDVG measurement)
Frequency
Single bolus at measurement times (one-time injection for IDVG measurement)
Maximum Dose
300 mg/kg/h

Related trials

Other published trials that may interest you.